Prostate Cancer Therapeutics Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis

Prostate Cancer Therapeutics Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Hormonal Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Geography

Publication Month : Dec 2023

  • Report Code : TIPRE00003423
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Inquire Before Buy

PRICING

$5190

$4671

[Research Report] The prostate cancer therapeutics market is expected to grow from US$ 14,767.73 million in 2022 to US$ 28,425.27 million by 2030; it is anticipated to record a CAGR of 8.5% from 2022 to 2030.

Market Insights and Analyst View:

The prostate cancer therapeutics market size is expanding with the rising R&D activities to introduce new drug compounds, increasing number of prostate cancer cases, and rising government support for diagnostics of prostate cancer. In addition, market players' availability of advanced products drives market growth. In January 2023, BDR Pharmaceutical launched a generic version of Apalutamide that is used to treat prostate cancer in India. The drug is launched under the brand APATIDE and is prescribed to treat non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

Growth Drivers and Challenges:

Prostate cancer is one of the most common health problems in men, especially in older men aged 50 years and above. Prostate cancer is mostly common in men who are obese and have a family history of prostate cancer. Prostate cancer is a silent threat as it often develops without noticeable symptoms. Hence, early detection of this cancer is not that easy. The majority of prostate cancers originate in the peripheral region of the prostate gland. For symptoms to become apparent, the cancer must reach a size where it exerts pressure on the urethra, or bone pain from the metastasis might be the initial presenting symptom of advanced prostate cancer in some cases. However, any individual aged 50 or above who presents with lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer. Prostate cancer is the fifth leading cause of cancer death among men across the world and the second most commonly diagnosed cancer. Even if there has been a decrease in the incidence of prostate cancer since 2000, there is an increase in the incidence of later-stage prostate cancer starting in 2010. Prostate cancer incidence rates and mortality rates differ greatly. Developed nations generally have a higher incidence of prostate cancer but lower mortality. The risk of prostate cancer in the US is almost four times greater than the global risk. According to the Novartis AG, in 2020, ~1.4 million new prostate cancer cases and about 375,000 prostate cancer deaths were reported worldwide. The increasing number of prostate cancer cases worldwide and the low detection rate of prostate cancer fuel the prostate cancer therapeutics market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Prostate Cancer Therapeutics Market: Strategic Insights

prostate-cancer-therapeutics-market
Market Size Value inUS$ 14,767.73 million in 2022
Market Size Value byUS$ 28,425.27 million by 2030
Growth rateCAGR of 8.5% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The prostate cancer therapeutics market is segmented based on therapy type, end user, and geography. The prostate cancer therapeutics market, by therapy type, is segmented into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. The prostate cancer therapeutics market, by end user, is segmented into hospitals, specialty clinics, and others. Based on geography, the prostate cancer therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Segmental Analysis:

The prostate cancer therapeutics market, by therapy type, is segmented into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. In 2022, the Hormone therapy segment held the largest market share after chemo therapy, and the same segment is expected to record the highest CAGR from 2022 to 2030. Chemotherapy is considered an important treatment for prostate cancer. In this therapy, drugs destroy the new or existing cancerous cells in the lungs. Chemotherapy for metastatic prostate cancer can alleviate symptoms. It can also help to reduce cancer and improve the quality of life. Docetaxel (Taxotere) is considered the standard of care in prostate cancer chemotherapy in patients who are resistant to hormone therapy. The FDA has also approved the chemotherapy drug cabazitaxel (Jevtana) for treating castration-resistant prostate cancer. It is also used for patients affected by metastatic prostate cancer that has grown while taking docetaxel.

Prostate Cancer Therapeutics Market, by End User – 2022 and 2030

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Regional Analysis:

The prostate cancer therapeutics market is segmented geographically into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the largest contributor to global prostate cancer therapeutics market growth. Asia Pacific is expected to register the highest CAGR in the prostate cancer therapeutics market from 2022 to 2030. The prostate cancer therapeutics market growth in the US is mainly driven by the increasing incidence of prostate cancer cases, product launches, and government initiatives. In June 2023, AstraZeneca and MSD’s Lynparza (olaparib) in combination with prednisone or prednisolone and abiraterone was approved in the US to treat adult patients with suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). In addition, in November 2023, the FDA approved enzalutamide, a product that Astellas Pharma US, Inc. manufactured. The product is used for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).

Industry Developments and Future Opportunities:

Various initiatives by key players operating in the prostate cancer therapeutics market are listed below:

  1. In March 2022, the US FDA approved Novartis’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients with a type of advanced prostate cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).
  2. In April 2023, the FDA granted Lantheus Holdings Inc and POINT Biopharma Global Inc fast track designation for 177Lu-PNT2002 for treating metastatic castration-resistant prostate cancer (mCRPC). PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines PSMA-targeted ligand, PSMA-I&T, and beta-emitting radioisotope no-carrier-added 177Lu for treating mCRPC.

Competitive Landscape and Key Companies:

Astella Pharma Inc, Johnson & Johnson Services Inc, Eli Lilly and Company, Bayer AG, Sanofi, Merck KGaA, AstraZeneca, Novartis AG, AbbVie, and Bristol Myers Squibb are among the prominent players operating in the prostate cancer therapeutics market. These market players focus on new product launches and geographic expansions to fulfill the growing consumer demand worldwide and increase their product range in specialty portfolios. Their global presence allows them to serve a large base of customers, subsequently facilitating market expansion.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Therapy Type, End User, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are prostate cancer therapeutics?

Prostate cancer is one of the most common health problems in men, especially in older men (aged above 50 years). Prostate cancer is mostly common in men who are obese and have a family history of prostate cancer. Prostate cancer is a silent threat that often develops without noticeable symptoms, and hence, early detection of this cancer is not that easy. Typically, the majority of prostate cancers originate in the peripheral region of the prostate gland. Consequently, for symptoms to become apparent, the cancer must reach a size where it exerts pressure on the urethra, or in some cases, bone pain from the metastasis might be the initial presenting symptom of advanced prostate cancer. However, any individual aged 50 or above who presents with lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer.

What are the driving and restraining factors for the prostate cancer therapeutics market?

The increasing cases of prostate cancer and strategic initiatives in prostate cancer therapeutics freezer bolster the prostate cancer therapeutics market size. However, the high cost associated with prostate cancer therapeutics hinders the growth of prostate cancer therapeutics market growth.

Who are the major players in the market the prostate cancer therapeutics market?

The prostate cancer therapeutics market majorly consists of players such Astella Pharma Inc, Johnson & Johnson Services Inc, Eli Lilly and Company, Bayer AG, Sanofi, Merck KGaA, AstraZeneca, Novartis AG, AbbVie, and Bristol Myers Squibb

Which segment is dominating the prostate cancer therapeutics market?

The prostate cancer therapeutics market, by therapy type, is segmented into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. In 2022, the chemotherapy segment held the largest market share, and the same segment is expected to record the highest CAGR from 2022 to 2030.
The prostate cancer therapeutics market, by end-user, is segmented into hospitals, specialty clinics, and others. In 2022, the hospital segment held the largest market share; moreover, the same segment is expected to record the highest CAGR during 2022–2030.

Which region is dominating the prostate cancer therapeutics market?

Based on geography, the prostate cancer therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to global prostate cancer therapeutics market growth. Asia Pacific is expected to register the highest CAGR in the prostate cancer therapeutics market from 2022 to 2030.

The List of Companies - Prostate Cancer Market

  1. Astella Pharma Inc
  2. Johnson & Johnson Services Inc
  3. Eli Lilly, and Company
  4. Bayer AG
  5. Sanofi
  6. Merck KGaA
  7. AstraZeneca
  8. Novartis AG
  9. AbbVie
  10. Bristol Myers Squibb

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Prostate Cancer Therapeutics Market